Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.
The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.
Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.
Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.
For more information, visit Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals (Nasdaq: ALNY) announced positive interim results from the Phase 1 clinical study of ALN-APP, an RNAi therapeutic targeting amyloid precursor protein for Alzheimer’s disease and cerebral amyloid angiopathy. The study enrolled 20 patients, revealing that single doses of ALN-APP achieved dose-dependent reductions of soluble APPα and APPβ in cerebrospinal fluid, with decreases of up to 90%. Safety and tolerability were encouraging, with only mild to moderate adverse events reported. This marks the first demonstration of RNAi gene silencing in the human brain, utilizing Alnylam's C16 platform. Further data will be disclosed at an upcoming scientific conference, and the trial continues to explore longer-term effects.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
What types of diseases does Regeneron Pharmaceuticals focus on?
What are some of Regeneron's key products?
Who are some of Regeneron's notable collaborators?
What recent financial steps has Regeneron taken?
How does Regeneron leverage genetic medicine?
What is the significance of Eylea in Regeneron's product portfolio?
What advancements has Regeneron made in gene therapy?
What is Dupixent used for?
What technologies does Regeneron use for drug development?
How does Regeneron contribute to scientific discovery?
